Sign In
Buy NOVN
$0.0941
+0 (+0%)
At Close: Nov 20, 2023
Peanut allergy is a growing health concern, especially in children, with rising incidence and increased public awareness of its severity and risks. This
Novartis AGcompleted the acquisition of Regulus Therapeutics Inc..
12:05pm, Wednesday, 25'th Jun 2025
Novartis AG (SWX:NOVN) submitted a written non-binding indication of interest to acquire Regulus Therapeutics Inc. (NasdaqCM:RGLS) for approximately $200 million on April 4, 2025. Novartis AG (SWX:NOV
– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan's assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 mil
Novan, Inc. (NOVN) Q1 2023 Earnings Call Transcript
03:07pm, Monday, 15'th May 2023
Novan, Inc. (NASDAQ:NOVN ) Q1 2023 Earnings Conference Call May 15, 2023 8:30 AM ET Company Participants Paula Brown Stafford - Chairman, President & Chief Executive Officer John Donofrio - Executive
Novan to Report First Quarter 2023 Financial Results on May 15, 2023
09:05am, Monday, 08'th May 2023
DURHAM, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2023 financial results on Monday, Ma
Novan to Report Full Year 2022 Financial Results on March 30, 2023
09:00am, Thursday, 23'rd Mar 2023
DURHAM, N.C., March 23, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its full year 2022 financial results on Thursday, Ma
Novan to Present at the Oppenheimer 33rd Annual Healthcare Conference
08:30am, Tuesday, 14'th Mar 2023
Presentation with live webcast today, March 14th at 10:40 AM ET Presentation with live webcast today, March 14th at 10:40 AM ET
Is WisdomTree International Equity ETF (DWM) a Strong ETF Right Now?
11:20am, Friday, 10'th Feb 2023 Zacks Investment Research
Smart Beta ETF report for DWM
Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDA
06:15am, Monday, 06'th Feb 2023 GlobeNewswire Inc.
Basel, February 06, 2023 — Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the US Food and Drug Administration (FDA) has accepted its Biologics License
Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®
11:30pm, Friday, 03'rd Feb 2023 GlobeNewswire Inc.
Basel, February 4, 2023 – Novartis announced today that The Lancet has published long-term data from the pivotal SUNSHINE and SUNRISE trials evaluating Cosentyx® (secukinumab) in moderate-to-severe
Novartis poursuit sa croissance avec une nouvelle expansion de sa marge core et franchit des étapes importantes dans l’innovation
06:00am, Wednesday, 01'st Feb 2023 GlobeNewswire Inc.
Annonce événementielle au sens de l’art. 53 RCExercice entier
Novartis continues to grow with further core margin expansion and achieves important innovation milestones
06:00am, Wednesday, 01'st Feb 2023 GlobeNewswire Inc.
Ad hoc announcement pursuant to Art. 53 LR
Novartis setzt Wachstumskurs mit weiterer Steigerung der Kerngewinnmarge fort und erreicht wichtige Innovations-meilensteine
06:00am, Wednesday, 01'st Feb 2023 GlobeNewswire Inc.
Ad-hoc-Mitteilung gemäss Art. 53 KR
Sandoz receives positive CHMP opinion for citrate-free high concentration formulation of adalimumab biosimilar
06:15am, Monday, 30'th Jan 2023 GlobeNewswire Inc.
Basel, January 30, 2023 — Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Med
Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio
11:30pm, Monday, 23'rd Jan 2023 GlobeNewswire Inc.
Basel, January 24, 2023 – Sandoz, the global leader in off-patent (generic and biosimilar) medicines, has signed an agreement to acquire worldwide product rights for leading systemic antifungal agen
